Galapagos discovers novel candidate drug to treat breast cancer

Galapagos discovers novel candidate drug to treat breast cancer 
MECHELEN, BELGIUM -- (Marketwired) -- 04/22/13 --    * GLPG1790 has
high efficacy against triple-negative breast cancer 
* Innovative, targeted approach 
* Galapagos plans to initiate clinical trials within one year 
Galapagos NV (EURONEXT BRUSSELS: GLPG) announced today that  it
developed  GLPG1790, a  novel candidate  drug to  treat breast
cancer.
GLPG1790 has shown high activity against breast tumors that
are triple- negative,
for  which the  absence of  estrogen (ER), 
progesterone (PR)  or HER2 receptors
affects  the prognosis  for
recovery,  and no  targeted therapeutic options are currently
available. 
Breast cancer is a disease in which tumor cells form in the breast
tissue; it is one of the most common types of cancer in women.  There
are many different types
of  breast  cancer,  and  as  a  result, 
there are many options for treatment.
Targeted  drug treatments such
as Herceptin(R) and Avastin(R)[1] attack specific types  of breast
cancer cells.  Decisions about the best possible treatment with
targeted  drugs are  based on  tests for  the presence  of ER,  PR
and HER2[2].
Triple-negative  breast  cancer  (tumor  cells  that 
have  no  ER, PR and HER2)
accounts  for one-fifth of breast cancers,
 and it usually affects young women.
There  are no targeted drugs
available  for patients with triple-negative breast
cancer. 
Candidate  drug GLPG1790 is a  selective and potent inhibitor  of a
novel breast
cancer target; the candidate drug has proven to be highly
active against triple-negative  breast cancer  in a  mouse xenograft
 model where it completely blocks
tumor  growth.  GLPG1790 has good 
drug-like properties, and safety/tolerability
studies  with  the 
candidate  drug  look  favorable.   Galapagos  will
initiate
preclinical  studies with GLPG1790,  and expects to 
initiate the first clinical
trials  in humans within one  year.  This
novel program  is fully proprietary to Galapagos. 
"GLPG1790 is the result of a multi-year research program on a novel
mechanism of action  discovered with our target discovery  platform,"
says Dr Piet Wigerinck,
Galapagos  CSO. "We  are pleased  to have 
developed a targeted approach towards
triple-negativ
e  breast cancer.
  Targeted approaches in oncology typically show
good efficacy and
less toxicity than chemotherapy." 
About Galapagos 
Galapagos  (EURONEXT BRUSSELS: GLPG) (PINKSHEETS: GLPYY) is
specialized in novel modes-of-action, with  a large  pipeline of 
four clinical,  seven pre-clinical, and 30 discovery small-molecule  
and   antibody   programs  in  cystic  fibrosis,
inflammation,
antibiotics, metabolic disease, and other indications.
GLPG0634  is an orally-available, selective inhibitor  of JAK1 for
the treatment
of  rheumatoid arthritis and  potentially other
inflammatory  diseases, about to enter  Phase  2b studies.   AbbVie 
and  Galapagos  signed  a  worldwide license
agreement  whereby 
AbbVie  will  be  responsible  for  further development and
commercialization   after   Phase  2b.  Galapagos  has  another 
selective JAK1
inhibitor  in Phase 2 in lupus and psoriasis,
GSK2586184 (formerly GLPG0778, in- licensed  by GlaxoSmithKline  in
2012).  GLPG0187  is a  novel integrin receptor
antagonist currently
in a Phase 1b patient study in metastasis.  GLPG0974 is the first 
inhibitor of FFA2  to be evaluated  clinically for the  treatment of
IBD;
this program will start a Proof of Concept Phase 2 study this
quarter. The  Galapagos Group, including fee-for-service  companies
BioFocus, Argenta and Fidelta,  has over 800 employees and operates
facilities in five countries, with
global headquarters in Mechelen,
Belgium.  Further information at: www.glpg.com 
This   release   may  contain  forward-looking  statements, 
including, without
limitation,   statements   containing   the   words
 "believes," "anticipates,"
"expects,"  "intends,"  "plans," 
"seeks,"  "estimates," "may," "will," "could,"
"stands  to," and 
"continues," as  well as  similar expressions.  Such forward-looking
 statements may involve known and unknown risks, uncertainties and
other
factors  which might cause the  actual results, financial
condition, performance
or  achievements of Galapagos,  or industry
results,  to be materially different
from  any  historic  or  future 
results,  financial  conditions, performance or achievements 
expressed  or  implied  by  such forward-looking statements.
Given
these  uncertainties, the reader is  advised not to place  any
undue reliance on such  forward-looking statements. These
forward-looking statements speak only as of  the date of publication
of  this document. Galapagos expressly disclaims any obligation  to
update  any such  forward-looking statements  in this document to
reflect  any change  in its  expectations with  regard thereto  or
any change in events, conditions or circumstances on which any such
statement is based, unless
required by law or
regulation. 
---------------------------------------------------------------------------
----- 
[1]Herceptin(R) and Avastin(R) are registered trademarks of Roche for
trastuzumab and bevacizumab, respectively 
[2]Human epidermal growth factor type 2 receptor 
This announcement
is distributed by Thomson Reuters on behalf of Thomson Reuters
clients. The owner of this announcement warrants that: 
(i) the releases contained herein are protected by copyright and    
other applicable laws; and 
(ii) they are solely responsible for the content, accuracy and     
originality of the information contained therein. 
Source: Galapagos NV via Thomson Reuters ONE 
[HUG#1694682] 
CONTACT 
Galapagos NV
Dr Piet Wigerinck
Chief Scientific Officer
Tel. +32 477 627103 
Elizabeth Goodwin
Director Investor Relations
Tel: +31 6 2291 6240
ir@glpg.com
 
 
Press spacebar to pause and continue. Press esc to stop.